Clinical Trial Update: A 3-fold Crossover Bioequivalence Study Between Glucobay Orally Disintegrating Tablet (ODT) and Glucobay Standard Tablet [Phase 1]

View source ↗

Summary

A Phase 1 crossover bioequivalence study comparing Glucobay orally disintegrating tablet to Glucobay standard tablet (acarbose) for Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Glucobay ODT (acarbose)
• Glucobay Standard Tablet (acarbose)

Snippet

Sponsor: Bayer | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED